| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3333774 | Seminars in Hematology | 2010 | 11 Pages |
Abstract
The development of newer strategies to overcome, in particular, the cell dose limitation, has increased the availability of umbilical cord blood (UCB) as a source of hematopoietic stem cells (HSC) for transplantation of adults. Among these strategies is the development of the double UCB, ex vivo, and reduced-intensity transplantation platforms. Several ongoing registry-based and single-institution and multicenter clinical trials are investigating ways to make UCB transplantation safer and to improve the outcomes of adults after UCB transplantation. We review the background data and promising newer strategies that will further expand the utilization of UCB for the treatment of adults.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Claudio G. Brunstein, Mary J. Laughlin,